Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy
Saved in:
| Published in: | Journal of Health Economics and Outcomes Research |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301677696024583 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Journal of Health Economics and Outcomes Research |
| description | |
| discipline_display | Health and Safety |
| discipline_facet | Health and Safety |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:69571 |
| institution | FRELIP |
| journal_source_facet | Journal of Health Economics and Outcomes Research |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy Health and Safety General Health and Safety |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Health and Safety General Health and Safety Health and Safety General Health and Safety |
| subject_facet | Health and Safety General Health and Safety |
| title | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_auth | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_full | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_fullStr | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_full_unstemmed | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_short | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_sort | estimated cost of adverse event management in treatment naïve non-small cell lung cancer patients with common egfr mutations treated with amivantamab plus lazertinib and osimertinib plus chemotherapy |
| topic | Health and Safety General Health and Safety |
| url | https://jheor.org/article/161356-estimated-cost-of-adverse-event-management-in-treatment-naive-non-small-cell-lung-cancer-patients-with-common-egfr-mutations-treated-with-amivantamab |